clinical trial · NCT06432647
A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105
LeonaBio·phase1·completed·n = 80
Healthy VolunteersATH-1105Placebo
brief summary
The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.
started
Apr 24, 2024
primary completion
Nov 25, 2024
completion
Nov 25, 2024
last updated
Jan 23, 2025
detailed description
The study is a Phase 1, First-In-Human study consisting of two parts (A and B). Part A will comprise a single-dose, double-blind, placebo-controlled, sequential-group design. Part B will comprise a multiple-dose, placebo-controlled, sequential-group design.
official title
ATH-1105 A Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol